Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALSTAR: Sildenafil in PAD
NCT02930811Phase 3Withdrawn
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Primary completion
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Primary endpoint: Improvement of Event free survival rate at 6 months. Status: withdrawn.
02
Drugs
ASP-001
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02930811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930811.